Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) shares were down 5.9% during trading on Monday . The company traded as low as $33.35 and last traded at $33.46. Approximately 80,931 shares traded hands during trading, a decline of 89% from the average daily volume of 745,996 shares. The stock had previously closed at $35.54.
Wall Street Analyst Weigh In
A number of analysts recently commented on AGIO shares. Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright started coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Scotiabank increased their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. Finally, StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $56.57.
Check Out Our Latest Analysis on Agios Pharmaceuticals
Agios Pharmaceuticals Price Performance
The company has a 50-day moving average of $33.82 and a two-hundred day moving average of $42.48. The stock has a market capitalization of $1.95 billion, a PE ratio of 3.00 and a beta of 0.88.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.
Insider Transactions at Agios Pharmaceuticals
In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.93% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in AGIO. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at $33,000. GF Fund Management CO. LTD. acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $39,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $53,000. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares in the last quarter. Finally, Quest Partners LLC grew its holdings in shares of Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 1,283 shares in the last quarter.
Agios Pharmaceuticals Company Profile
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Recommended Stories
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
